skip to Main Content

UTEST program bends career road for Granata Decision Systems’ founders

TGranata Decision System logo Nov 2013ORONTO (January 21, 2015) — MaRS Innovation and the University of Toronto (U of T) are pleased to announce that the founders of Granata Decision Systems Inc., a graduate of the University of Toronto Early-Stage Technology (UTEST) start-up incubator program, have joined Google Inc.

This story was covered in TechVibes.

Dr. Craig Boutilier is a professor in U of T’s Department of Computer Science. He and Tyler Lu, a graduating PhD student in the same department, co-founded Granata Decision Systems in 2012 to develop their advanced decision-support technologies. Granata’s software platform provided real-time optimization and scenario analysis capabilities for large-scale, data-driven marketing problems and group/organizational decision-making. The company was part of the UTEST program’s first cohort.

“This is a significant milestone for the UTEST program and the wider MaRS Innovation portfolio,” said Dr. Raphael Hofstein, president and CEO. “We co-created the UTEST program with U of T to foster entrepreneurship in a meaningful way while encouraging students and professors to translate their academic ideas into commercial realities. We hope Craig and Tyler’s success will motivate other researchers and students to consider working with MI and participate in UTEST and our other commercialization programs.”

Continue Reading

Wound Healing Technology Exclusive Rights Deal with Cardium Therapeutics

TORONTO
 (October
 14,
 2010)
 –
 Of
 the
 approximately
 300
 million
 people
 around
 the
 world
 who
 are
 diabetics,
 45
 million
 of
 them
 develop 
foot
 ulcers 
that 
bleed
 – 
and 
the 
infection
 from
 those 
ulcers
 can 
spread.

University of Toronto
University of Toronto

Working
 to
 halt
 this
 is
 Dr.
 Ping
 Lee,
 a
 professor
 at
 the
 University
 of
 Toronto’s (U of T)
 Leslie
 Dan
 Faculty
 of
 Pharmacy and
 GlaxoSmithKline chair
 in
 Pharmaceutics
 and 
Drug 
Delivery.
 He 
and 
his
 team
 have 
created 
a 
new 
sustained‐release
 form
 of
 nitric 
oxide 
(NO) 
that
 can
 not
 only
 stop 
the 
infections 
at
 wound
sites, 
but
 also
 has
 the
 potential 
to
speed
 up
 wound‐healing.

Still,
 the
 technology
 may
 have
 stayed
 on
 the
 shelf,
 even
 with
 three
 years
 worth
 of
 data
 demonstrating
 therapeutic
 relevance.
 The
 ultimate
 success
 of
 the
 technology
 is
 due
 to
 an
 effective
 collaboration
 between
 Dr.
 Lee,
 the
 Innovations
 and
 Partnerships
 Office
 (IPO)
 at
 U
 of
 T
 and
 MaRS
 Innovation (MI).
 Lee
 worked
 with
 IPO
 and
 MI to
 formulate
 a
 development
 plan
 in
 consultation
 with 
numerous 
industry
 advisors.

Continue Reading
Back To Top